UBS analyst, Jonathan Groberg, raised his PT on Charles River Labs (NYSE: CRL) to $83 from $76 but maintained his ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE